CN104856964B - 丙氨酰谷氨酰胺冻干制剂及其制备方法 - Google Patents
丙氨酰谷氨酰胺冻干制剂及其制备方法 Download PDFInfo
- Publication number
- CN104856964B CN104856964B CN201410059863.6A CN201410059863A CN104856964B CN 104856964 B CN104856964 B CN 104856964B CN 201410059863 A CN201410059863 A CN 201410059863A CN 104856964 B CN104856964 B CN 104856964B
- Authority
- CN
- China
- Prior art keywords
- alanyl glutamine
- glutamine
- temperature
- alanyl
- superfine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 title claims abstract description 95
- 229960002648 alanylglutamine Drugs 0.000 title claims abstract description 95
- 108010044940 alanylglutamine Proteins 0.000 title claims abstract description 95
- 238000009472 formulation Methods 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 111
- 239000000843 powder Substances 0.000 claims abstract description 39
- 238000001035 drying Methods 0.000 claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000012065 filter cake Substances 0.000 claims abstract description 14
- 239000012043 crude product Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000005406 washing Methods 0.000 claims abstract description 12
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000460 chlorine Substances 0.000 claims abstract description 7
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 7
- 239000012141 concentrate Substances 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 238000010792 warming Methods 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 238000001953 recrystallisation Methods 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 3
- 238000002425 crystallisation Methods 0.000 claims abstract description 3
- 230000008025 crystallization Effects 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims 1
- 238000005516 engineering process Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- YIJVJUARZXCJJP-WHFBIAKZSA-N (2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 YIJVJUARZXCJJP-WHFBIAKZSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000012395 formulation development Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410059863.6A CN104856964B (zh) | 2014-02-21 | 2014-02-21 | 丙氨酰谷氨酰胺冻干制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410059863.6A CN104856964B (zh) | 2014-02-21 | 2014-02-21 | 丙氨酰谷氨酰胺冻干制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104856964A CN104856964A (zh) | 2015-08-26 |
CN104856964B true CN104856964B (zh) | 2016-01-27 |
Family
ID=53903440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410059863.6A Active CN104856964B (zh) | 2014-02-21 | 2014-02-21 | 丙氨酰谷氨酰胺冻干制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104856964B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110093047A (zh) * | 2018-01-31 | 2019-08-06 | 上海汇友精密化学品有限公司 | 一种染料的超细化处理技术 |
CN112569194A (zh) * | 2020-12-31 | 2021-03-30 | 南京肽谷生物科技有限公司 | 一种丙氨酰谷氨酰胺冻干粉的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070484A1 (en) * | 2003-09-26 | 2005-03-31 | Josef Neu | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
CN102491918A (zh) * | 2011-11-28 | 2012-06-13 | 海南灵康制药有限公司 | 一种丙氨酰谷氨酰胺化合物及其制法 |
-
2014
- 2014-02-21 CN CN201410059863.6A patent/CN104856964B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070484A1 (en) * | 2003-09-26 | 2005-03-31 | Josef Neu | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
CN102491918A (zh) * | 2011-11-28 | 2012-06-13 | 海南灵康制药有限公司 | 一种丙氨酰谷氨酰胺化合物及其制法 |
Also Published As
Publication number | Publication date |
---|---|
CN104856964A (zh) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2829275B1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
CN101869551B (zh) | 一种替莫唑胺冻干制剂 | |
Sun et al. | An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer | |
CN101429254A (zh) | 一种白及多糖及其制备方法和新用途 | |
JP6794366B2 (ja) | シリビン、l−カルニチンを含有する薬物組成物 | |
JP6656316B2 (ja) | ハマナツメの使用方法、ハマナツメ抽出物の使用方法及び薬物混合物の使用方法 | |
CN101095670B (zh) | 木犀草素磷脂复合物及其制备方法和应用 | |
JP6389958B2 (ja) | 瓦草5環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
CN104856964B (zh) | 丙氨酰谷氨酰胺冻干制剂及其制备方法 | |
CN102178956A (zh) | 20S-原人参二醇β-环糊精包合物制备及其医药用途和组合物 | |
WO2017092230A1 (zh) | 双黄酮化合物及其治疗癌症和制备药物的用途 | |
WO2012028056A1 (zh) | 一种灯盏花乙素临床制剂及其制备方法 | |
CN101897667B (zh) | 一种盐酸多柔比星脂质体注射剂及其制备工艺 | |
WO2020156330A1 (zh) | 一种用于治疗人恶性脑胶质瘤或黑色素瘤的番荔枝种子提取物及其制备方法和应用 | |
CN106220605A (zh) | 一种制备治疗呼吸道炎症的厄多司坦化合物的方法 | |
CN104127388A (zh) | 卡络磺钠特种超细粉体冻干制剂及其制备方法 | |
CN104326937B (zh) | 抗肿瘤化合物及其医药用途 | |
CN103864776B (zh) | 一种含1,3,4-噻二唑杂环及酰胺基团的替加氟衍生物 | |
CN103720666B (zh) | 一种注射用硼替佐米冻干制剂的制备方法 | |
CN106727349A (zh) | 一种浓缩水牛角颗粒的制备方法 | |
CN102631386B (zh) | 柴胡解热镇痛制剂及其制备工艺 | |
CN103159710B (zh) | 用于抗病毒的十氢萘衍生物 | |
CN111514133A (zh) | 木香烃内酯和/或去氢木香内酯在制备治疗黑色素瘤的药品中的应用 | |
CN104109128A (zh) | 卡博替尼苹果酸盐及其制备方法 | |
CN106236842B (zh) | 宽筋藤抑制hdac1酶有效部位及制法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Jiang Xiaodong Inventor after: Li Fengsheng Inventor after: Hao Hongxun Inventor before: Jiang Xiaodong Inventor before: Li Fengsheng |
|
COR | Change of bibliographic data | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151113 Address after: 310000 No. 1, No. 1 Avenue, Hangzhou economic and Technological Development Zone, Zhejiang Applicant after: Hainan Lingkang Pharmaceutical Co.,Ltd. Applicant after: Tianjin University Address before: 310000 No. 1, No. 1 Avenue, Hangzhou economic and Technological Development Zone, Zhejiang Applicant before: Hainan Lingkang Pharmaceutical Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Jiang Xiaodong Inventor after: Li Fengsheng Inventor after: Hao Hongxun Inventor after: Li Chunli Inventor after: Wang Honghai Inventor before: Jiang Xiaodong Inventor before: Li Fengsheng Inventor before: Hao Hongxun |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160329 Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee after: Hainan Lingkang Pharmaceutical Co.,Ltd. Patentee after: Tianjin University Patentee after: Hebei University of Technology Address before: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building Patentee before: Hainan Lingkang Pharmaceutical Co.,Ltd. Patentee before: Tianjin University |